Skip to content

Real-World Study on the Efficacy of MOVE Lenses in Slowing Myopia Progression in Children

Real-World Study on the Efficacy of MOVE Lenses in Slowing Myopia Progression in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129624
Enrollment
Unknown
Registered
2026-08-07
Start date
2026-08-10
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractive error

Interventions

ZEISS MOVE Myopia Control Spectacle Lenses Group:None

Sponsors

The Zhongshan Ophthalmic Center,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Accompanied by parents or legal guardians who can read and understand Chinese, with written informed consent signed by guardians; 2. Aged from 6 to 16 years old (inclusive) at baseline enrollment; 3. Diagnosed with myopia, with cycloplegic spherical equivalent refraction ranging from -0.50 D to -9.00 D, and combined refractive power not exceeding -9.00 D in both eyes; 4. Absolute astigmatism = 0.8 in both eyes; 6. Both eyes are normal without other ocular abnormalities or diseases except refractive error.

Exclusion criteria

Exclusion criteria: 1. History of using any myopia control interventions within 3 months prior to study enrollment, including contact lenses, atropine, specially designed contact lenses/spectacles with claimed myopia control efficacy, light therapy devices for myopia control, etc.; 2. History of ocular trauma or eye surgery; or suffering from any ocular/systemic diseases that may affect myopia progression or refractive status, or receiving drug treatment that impairs vision; 3. Diagnosis of amblyopia; 4. Manifest strabismus; 5. Concurrent participation in another clinical study.

Design outcomes

Primary

MeasureTime frame
Success rate of myopia control with ZEISS MOVE lenses assessed by cycloplegic spherical equivalent change;

Secondary

MeasureTime frame
Incidence of all ocular and lens-wearing related adverse events within 12 months;Proportion of subjects with axial length elongation less than 0.2 mm during 12-month follow-up;

Countries

China

Contacts

Public ContactXiao Yang

The Zhongshan Ophthalmic Center,Sun Yat-sen University

yangxiao@gzzoc.com+86 20 87330410

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026